Dr. PC Zhu is a scientist and entrepreneur with a distinguished track record in biomedical innovation and leadership. He holds a PhD from Fudan University and an MBA from the Chicago Booth, and completed postdoctoral research at Harvard Medical School. His pioneering work on AOC technology was highlighted by Nature Milestones as one of 15 key milestones in the field.

As Founder and President of Mass Innovation Labs in Boston, Dr. Zhu helped incubate seven biotech companies that went public, including CRISPR Therapeutics, Editas Medicine, Gritstone, and C4 Therapeutics. Today, he leads ATLATL Innovation Center, a global biomedical R&D platform serving more than 300 teams through a network of hubs in Shanghai, Beijing, Singapore, Hong Kong, and beyond. ATLATL’s member companies have generated more than $15 billion in licensing deal value.

Dr. Zhu was recognized by Forbes in 2024 for his contributions to advancing the life sciences. ATLATL has also been named one of the “50 Most Innovative Companies” by The Silicon Review.